Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 116-119 , May 2008

False-positive cells in sentinel lymph nodes

  • Jeoffry B. Brennick, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Jeoffrey B. Brennick, MD, Department of Pathology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03755.
    • ,
  • Shaofeng Yan, MD

References 

  1. Yan S, Brennick JB. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Am J Surg Pathol. 2004;28:596–600
  2. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976–982
  3. Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes (A prospective incidence and immunohistochemical study with literature review). Am J Clin Pathol. 1994;102:102–108
  4. Fisher CJ, Hill S, Millis RR. Benign lymph node inclusions mimicking metastatic carcinoma. J Clin Pathol. 1994;47:245–247
  5. Hruban RH, Eckert F, Baricević B. Melanocytes of a melanocytic nevus in a lymph node from a patient with a primary cutaneous melanoma associated with a small congenital nevus. Am J Dermatopathol. 1990;12:402–407
  6. Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer. 1977;39:164–171
  7. McCarthy SW, Palmer AA, Bale PM, et al. Naevus cells in lymph nodes. Pathology. 1974;6:351–358
  8. Biddle DA, Evans HL, Kemp BL, et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol. 2003;27:673–681
  9. Stewart FW, Copeland MM. Neurogenic sarcoma. Am J Cancer. 1931;15:1235–1320
  10. Johnson WT, Helwig EB. Benign nevus cells in the capsule of lymph nodes. Cancer. 1969;23:747–753
  11. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139–146
  12. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 2003;11:11–15
  13. Baisden BL, Askin FB, Lange JR, et al. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 2000;24:1140–1146
  14. Ulmer A, Fischer JR. Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes. Clin Cancer Res. 2005;11:5425–5432
  15. Satzger I, Völker B, Meier A, et al. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol. 2007;31:1175–1180
  16. Boi S, Cristofolini P, Togni R, et al. Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res. 2002;12:147–153
  17. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for staging of melanoma. J Clin Oncol. 2006;24:2849–2857
  18. Gutzmer R, Kaspari M, Brodersen JP, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology. 2002;41:510–518
  19. Giblin AV, Hayes AJ, Thomas JM. The significance of melanoma micrometastases in the sentinel lymph node. Eur J Surg Oncol. 2005;31:1103–1104
  20. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol. 2006;17:1578–1585
  21. Govindarajan A, Ghazarian DM, McCready DR, et al. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol. 2007;14:906–912
  22. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol. 2005;12:440–448
  23. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol. 2004;11(suppl):162S–168S
  24. Carlson GW, Murray DR, Lyles RH, et al. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance?. Ann Surg Oncol. 2003;10:575–581
  25. Ranieri JM, Wagner JD, Azuaje R, et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol. 2002;9:975–981
  26. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the AJCC Cancer Staging Manual. Cancer. 2003;98:2740–2741
  27. Singletary SE, Allred C. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  28. Fournier K, Schiller A. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg. 2004;239:859–863
  29. Rutgers EJ. Sentinel node micrometastasis in breast cancer. Br J Surg. 2004;91:1241–1242
  30. Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol. 2007;14:2861–2866
  31. Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group (Sentinel-node biopsy or nodal observation in melanoma). N Engl J Med. 2006;355:1307–1317

PII: S0740-2570(08)00022-1

doi: 10.1053/j.semdp.2008.03.001

Seminars in Diagnostic Pathology
Volume 25, Issue 2 , Pages 116-119 , May 2008

Article Tools